We serve Chemical Name:icosan-3-one CAS:2955-56-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:icosan-3-one
CAS.NO:2955-56-8
Synonyms:3-Icosanone;Ethylheptadecyl ketone;Aethyl-heptadecyl-keton;Eicosan-3-on;Aethyl-n-heptadecyl-keton;3-EICOSANONE
Molecular Formula:C20H40O
Molecular Weight:296.53100
HS Code:2914190090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:350.9ºC at 760mmHg
Density:0.833g/cm3
Index of Refraction:1.445
PSA:17.07000
Exact Mass:296.30800
LogP:7.22700
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Icosanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-EICOSANONE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethylheptadecyl ketone Use and application,3-EICOSANONE technical grade,usp/ep/jp grade.
Related News: According to statistics from the Price Supervision and Competition Bureau of the National Development and Reform Commission, China can produce more than 1,500 kinds of bulk drugs, with a total output of one million tons and an export volume of more than 60%. It has become the world’s second largest drug substance after the United States. Country of manufacture and largest exporter. icosan-3-one manufacturer According to statistics from the Price Supervision and Competition Bureau of the National Development and Reform Commission, China can produce more than 1,500 kinds of bulk drugs, with a total output of one million tons and an export volume of more than 60%. It has become the world’s second largest drug substance after the United States. Country of manufacture and largest exporter. icosan-3-one supplier The data will be updated at the upcoming 2019 ASH Annual Meeting next week. icosan-3-one vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). icosan-3-one factory This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug.
